Interestingly, and in sharp contrast to KMT2A-r models, BCL-2+BCR::ABL1 mutated samples did not respond to VEN application, with similar blast kinetics and tumor cell frequencies in controls and treated animals (Fig. 7A, B, lower panels). This evidence concerns the gene ABL1 and neoplasm.